The effectiveness of a fixed double combination (bisoprolol, perindopril) in patients with stable coronary artery disease and arterial hypertension different degrees
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Main Article Content
Abstract
The aim – to evaluate the hypotensive and antianginal efficacy of a fixed double combination (bisoprolol, perindopril) in patients with coronary artery disease (CAD) and concomitant hypertension.
Materials and methods. The study involved 170 cardiologists from various regions of Ukraine. Each researcher selected 15 consecutive outpatients with coronary heart disease who came for a regular visit. Inclusion criteria: age over 18 years old, blood pressure (BP) above 140/90 mm Hg, heart rate (HR) above 60 bpm, bisoprolol as part of antihypertensive therapy in the last ≥ 3 months. The study included two visits. At each visit, the patient’s objective status was assessed; an individual questionnaire with office systolic and diastolic blood pressure, heart rate, ECG data, clinical manifestations of CAD, risk factors, lifestyle features, concomitant diseases, current therapy was filled out. Medication adherence was also evaluated, the therapy was corrected if necessary and the presence of side effects and adverse events was registered. We analyzed the levels of BP and HR at the beginning and at the end of the study, the percentage of achievement of the recommended levels of these indicators, the antianginal efficacy of treatment and adherence to therapy in patients with CAD and different degrees of hypertension after 4 weeks of treatment.
Results and discussion. 2785 patient questionnaires were provided by doctors, 1747 patients were included in substudy. The mean age of the patients was 60.9±10.2 years old, men – 57.1 %, women – 42.9 %. The diagnosis of coronary artery disease was based on: chest pain – 554 (31.7 %), a history of documented myocardial infarction – 935 (53.5 %), coronary ventriculography – 536 (30.7 %), revascularization (CABG/stenting) – 344 (19.8 %) patients. The use of a fixed combination of previously taken drugs (perindopril, bisoprolol) for 4 weeks allows to reduce heart rate and blood pressure effectively (HR ≤ 70 bpm reached 84.9 % of patients, BP ≤ 140/90 mm Hg – 86.9 %), to reduce the number of angina attacks (from 4.48, 4.5 and 4.7 per week at the beginning of the study to 2.4; 2.9 and 2.3 per week in patients with 1, 2 and 3 degrees of hypertension, respectively) and the need for nitroglycerin from from 4.5; 4.9 and 5.9 tab per week up to 2.4; 2.9 and 2.3 tab per week. The most significant absolute decrease of BP and HR was in patients with a more severe degree of hypertension (decrease systolic BP was – 40.8 mm Hg, diastolic BP – 21.4 mm Hg, HR – 21.8 bpm).
Conclusions. The study demonstrated that the use of the fixed combination of bisoprolol and perindopril in patients with coronary artery disease and concomitant hypertension (different degrees) helps to improve treatment efficacy, to achieve recommended levels of blood pressure and heart rate, also has a significant antianginal effect (reliable decrease of the number of angina attacks and the need to take nitroglycerin) and increases adherence to therapy.
Article Details
Keywords:
References
Лутай М.І., Пархоменко О.М., Лисенко Г.Ф. та ін. Пацієнт зі стабільною ішемічною хворобою серця в Україні та Європі: результати 5-річного реєстру CLARIFY // Укр. кардіол. журн.– 2018.– № 4.– С. 19–30.
Лутай М.І., Голікова І.П. Лікування пацієнтів з ішемічною хворобою серця та артеріальною гіпертензією: результати дослідження ПРЕСТОЛ // Укр. кардіол. журн.– 2019.– № 1.– С. 19–30.
Серцево-судинні захворювання. Класифікація, стандарти діагностики та лікування / За ред. В.М. Коваленка, М.І. Лутая, Ю.М. Сіренка, О.С. Сичова.– К., 2021.– 320 с.
Стабільна ішемічна хвороба серця (адаптована клінічна настанова, заснована на доказах, 2016) // Артеріальна гіпертензія.– 2016.– № 2 (46).– С. 113–126.
Bertrand M.E., Ferrari R., Remme W.J. et al. Perindopril and ß-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: A European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis // Amer. Heart J.– 2015.– Vol. 170 (6).– P. 1092–1098.
Brugts J.J., Bertrand M., Remme W. et al. The Treatment Effect of an ACE-Inhibitor Based Regimen with Perindopril in Relation to Beta-Blocker use in 29,463 Patients with Vascular Disease: a Combined Analysis of Individual Data of ADVANCE, EUROPA and PROGRESS Trials // Cardiovasc. Drugs. Ther.– 2017.– Vol. 31 (4).– P. 391–400.
Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension: Erratum // J. Hypertens.– 2019.– Vol. 37 (2).– P. 456.
ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC) // Eur. Heart J.– 2020.– Vol. 41 (3).– P. 407–477.
ESС Guidelines on cardiovascular disease prevention in clinical practice // Eur. Heart J.– 2021.– Vol. 42 (34).– P. 3227–3337.
Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised: double-blind, placebo-controlled, multicentre trial (the EUROPA study) // Lancet.– 2003.– Vol. 362 (9386).– P. 782–788.
Rodriguez-Granillo G.A.,: Vos J., Bruining N. et al. Investigators of the EUROPA Study. Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril’s prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study) // Am. J. Cardiol.– 2007.– Vol. 100 (2).– P. 159–163.
Rosendorff C., Lackland D.T., Allison M. et al. American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension // Hypertension.– 2015.– Vol. 65 (6).– P. 1372–1407.
Von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators // JACC.– 1995.– Vol. 25 (1).– P. 231–238.